Abstract Details

Title Predictors of In-Hospital Mortality after Acute Ischemic Stroke

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P01 - (-)

Poster/Presentation
Number 227

Objective

Background BACKGROUND: Minimal predictors exist for acute stroke prognosis. We sought to answer this important question with a large universal database.

Design/Methods DESIGN/METHODS: Pooled data from the 3 UHC studies was collected and patients dichotomized as follows: death during initial hospitalization and patients discharged from the hospital (home, rehabilitation). Using Chi square and T-tests, univariate analysis was performed on the following: age, gender, stroke severity, post stroke complications co-morbid cardiovascular, pulmonary and neurological conditions including prior stroke or TIA and prior medication use; LLA, antihypertensives, aspirin, other antiplatelet agents and anticoagulants. Predictors with a p value of <0.1 were included in the final multivariate regression analysis to determine predictors of mortality.

Results RESULTS: Of the 3522 patients, 201 died after AIS. Mean age was 67.11± 14.96 years and there was no gender difference (49.8%male, 50.2% females). Univariate predictors of mortality were stroke severity (P<0.001) and post stroke complications (P< 0.001). ASA (P<0.001), other antiplatelet agents (P< 0.001) were associated with reduced mortality. LLA demonstrated a trend (p=0.08). In the final multivariate logistic regression analysis, stroke severity (P< 0.001,OR 4.98,CI3.39-7.32) and post stroke complications(P<0.001,OR 22.22,CI 12.34-40) were associated with increased mortality while ASA (p=0.007,OR0.65,CI0.47-0.89) and other antiplatelet drugs(P=0.01,OR0.62,CI 0.42-0.9) were negative predictors of mortality. LLA, antihypertensives and anticoagulants were not predictors of mortality.

Conclusions CONCLUSIONS: After AIS, patients with severe stroke and post stroke complications were 5 and 22.2 times more likely to die while ASA and other antiplatelet agent use before AIS were associated respectively with 1.6 and 1.5 times greater chances of survival after AIS. Unlike previous reports from smaller studies, LLA were not predictive of in-patient mortality.

Authors/Disclosures
Majaz Moonis, MD, FAHA, FAAN (University of Massachusetts, Department of Neurology) PRESENTER	Dr. Moonis has nothing to disclose.
	No disclosure on file
	No disclosure on file
Banu Sundar, MD	Dr. Sundar has nothing to disclose.
Daniela Bota, MD (UCI Center for Clinical Research, Irvine Hall)	No disclosure on file

��ɫ��

��ɫ��